Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs

International Journal of Rheumatic Diseases

Volumn 19, Issue 5, 2016, Pages 470-475

  Nakamura, Jun ^a   Nagashima, Takao ^a   Nagatani, Katsuya ^a   Yoshio, Taku ^a   Iwamoto, Masahiro ^a   Minota, Seiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

de novo hepatitis; Hepatitis B virus; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS DNA; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; HEPATITIS B ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; DAS28; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VIRUS REACTIVATION; ARTHRITIS, RHEUMATOID; BLOOD; CASE REPORT; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; JAPAN; PATHOGENICITY; RISK FACTOR; TIME FACTOR; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOMARKERS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; VIRAL LOAD; VIRUS ACTIVATION;

EID: 84897352169     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12359     Document Type: Article

References (32)

1. Komano Y, Tanaka M, Nanki T et al. (2011) Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese rheumatoid arthritis patients for longterm safety. J Rheumatol 38, 1258-64.
2. Komano Y, Harigai M, Koike R et al. (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum 61, 305-12.
3. Tanaka M, Sakai R, Koike R et al. (2012) Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Mod Rheumatol 22, 849-58.
4. Urata Y, Uesato R, Tanaka D et al. (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21, 16-23.
5. Lubel JS, Angus PW (2010) Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 25, 864-71.
6. Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46, 160-70.
7. Kusumoto S, Tanaka Y, Mizokami M, Ueda R (2009) Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90, 13-23.
8. Umemura T, Tanaka E, Kiyosawa K, Kumada H (2008) Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47, e52-6.
9. Oketani M, Ido A, Uto H, Tsubouchi H (2012) Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42, 627-36.
10. Kusumoto S, Tanaka Y, Ueda R, Mizokami M (2011) Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 46, 9-16.
11. Tamori A, Koike T, Goto H et al. (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46, 556-64.
12. Mori S (2011) Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 21, 621-7.
13. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al. (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69, 1352-5.
14. Charpin C, Guis S, Colson P et al. (2009) Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 11, R179.
15. Caporali R, Bobbio-Pallavicini F, Atzeni F et al. (2010) Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 62, 749-54.
16. Lan JL, Chen YM, Hsieh TY et al. (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70, 1719-25.
17. Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-24.
18. Lin CL, Kao JH (2011) The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 26 (Suppl 1), 123-30.
19. Takeuchi T, Tatsuki Y, Nogami Y et al. (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67, 189-94.
20. Koike T, Harigai M, Inokuma S et al. (2009) Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol 36, 898-906.
21. Koike T, Harigai M, Ishiguro N et al. (2013) Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod Rheumatol. doi: 10.3109/14397595.2013.843760. [Epub ahead of print].
22. Matsumoto T, Marusawa H, Dogaki M, Suginoshita Y, Inokuma T (2010) Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 30, 1241-2.
23. Montiel PM, Solis JA, Chirinos JA, a Casis B, Sanchez F, Rodriguez S (2008) Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 28, 718-20.
24. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M (2007) Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 13, 508-9.
25. Germanidis G, Hytiroglou P, Zakalka M, Settas L (2012) Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 56, 1420-1.
26. Fanouriakis A, Vassilopoulos D, Repa A, Boumpas DT, Sidiropoulos P (2014) Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection. Rheumatology (Oxford) 53, 195-6.
27. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2, 1104-8.
28. Raimondo G, Caccamo G, Filomia R, Pollicino T (2013) Occult HBV infection. Semin Immunopathol 35, 39-52.
29. Gwak GY, Koh KC, Kim HY (2007) Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 25, 888-9.
30. Tan J, Zhou J, Zhao P, Wei J (2012) Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 31, 1169-75.
31. Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y (2012) Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 22, 470-3.
32. Loras C, Gisbert JP, Minguez M et al. (2010) Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 59, 1340-6.